USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/16753
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRodoman, Iulia
dc.contributor.authorPalii, Ina
dc.contributor.authorSacara, Victoria
dc.contributor.authorGladun, Sergiu
dc.date.accessioned2021-05-08T15:45:23Z
dc.date.available2021-05-08T15:45:23Z
dc.date.issued2021
dc.identifier.citationRODOMAN, Iulia, PALII, Ina, SACARA, Victoria, GLADUN, Sergiu. Cardiomyopathy secondary to Duchenne muscular dystrophy in children. In: The Moldovan Medical Journal. 2021, vol. 64, no 2, pp. 70-78. ISSN 2537-6381. DOI: https://doi.org/10.52418/moldovan-med-j.64-2.21.13
dc.identifier.issn2537-6381
dc.identifier.issn2537-6373
dc.identifier.urihttp://moldmedjournal.md/wp-content/uploads/2021/05/64-2-Spaltul-2-vers-3-din-05-05.pdf
dc.identifier.urihttps://doi.org/10.52418/moldovan-med-j.64-2.21.13
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/16753
dc.descriptionCardiology Unit, Institute of Mother and Child, Chisinau, the Republic of Moldova, Department of Pediatrics, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, the Republic of Moldovaen_US
dc.description.abstractAbstract. Background: Cardiomyopathy (CM) associated with Duchenne muscular dystrophy (DMD) is a commonly recognized appearance of this neuromuscular disease, significantly increased morbidity and mortality, as well as the necessity for cardiological management. CM in DMD is defined by left ventricular (LV) systolic dysfunction and both atrial and ventricular dysrhythmias and is associated with higher mortality than other cases of pediatric dilated CMs. Notwithstanding the high rate of cardiac involvement, patients are usually asymptomatic despite significant LV dysfunction, because of likely poor mobility that masks the usual heart failure (HF) symptoms. Also, imagistic predictors are provided to be very helpful in defining early LV dysfunction, especially electrocardiogram and cardiac imaging (transthoracic echocardiography, speckle-tracking, cardiac magnetic resonance) are used to detect the onset and progression of dilated cardiomyopathy (DCM) in DMD. Conclusions: As most DMD patients are asymptomatic for a long time of their life, so identifying predictors of HF is crucial to support these patients. Ventricular dysfunction based on the ejection fraction (EF) measurement helps to choose therapy. In the case of early DCM (LVEF≥50%) the great purpose is to prevent ventricular dysfunction incipience with first-line HF therapy with Angiotensin-converting-enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs). Current guidelines recommend the use of conventional HF medication in case of disease progression and DCM with MidRange Reduction of LV EF (40-49%). The therapeutic approach for patients with DCM and severe ventricular dysfunction (<40%) has been studied less profoundly and contemporary guidelines recommend all drugs used for HF treatment.en_US
dc.language.isoenen_US
dc.publisherThe Scientific Medical Association of the Republic of Moldovaen_US
dc.relation.ispartofThe Moldovan Medical Journalen_US
dc.subjectDuchenne muscular dystrophyen_US
dc.subjectcardiomyopathyen_US
dc.subjectheart failureen_US
dc.subjectneuromuscularen_US
dc.subject.ddcUDC: 616.124-008.46:616.74-007.17-053.2en_US
dc.titleCardiomyopathy secondary to Duchenne muscular dystrophy in childrenen_US
dc.typeArticleen_US
Appears in Collections:The Moldovan Medical Journal, Vol. 64, No 2, June 2021

Files in This Item:
File Description SizeFormat 
Cardiomyopathy_secondary_to_Duchenne_muscular_dystrophy_in_children.pdf218.53 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback